Features | Partner Sites | Information | LinkXpress
Sign In
SCHILLER AG
TERARECON, INC.
AMPRONIX

Optical Coherence Tomography Shown to Predict Tumor Margins Effectively

By Medimaging International staff writers
Posted on 28 Jan 2013
Image: The VivoSight optical coherence tomography (OCT) scanner (Photo courtesy of Michelson Diagnostics).
Image: The VivoSight optical coherence tomography (OCT) scanner (Photo courtesy of Michelson Diagnostics).
A precise determination of tumor margins is vital for the effective treatment of skin cancer patients. This is particularly true for patients undergoing Mohs micrographic surgery, where complete tumor removal may require repeated invasive procedures.

Recent studies conducted in two US Healthcare facilities used the VivoSight optical coherence tomography (OCT) scanner, manufactured by Michelson Diagnostics, Ltd. (South London, UK), to prospectively improve clinically estimated tumor margins prior to Mohs micrographic surgery.

The first, a 52-patient study, conducted by Prof. Dan Seigel, from the department of dermatology, State University of New York Downstate Medical Center (Brooklyn, NY, USA), concluded that “OCT assessment has the potential to reduce the excised area without compromising the integrity of tumor-free borders.” The study’s findings were published January 2013 in the journal Dermatologic Surgery.

Another case study of a patient with very ill defined margins concluded that, “High-resolution imaging with a multibeam OCT device can accurately predict tumor margins of a BCC prior to Mohs micrographic surgery […] with any tumor, particularly ill-defined ones, the use of OCT could potentially reduce the number of stages required to clear the tumor leading to shorter operative times and reduction of cost.”

The findings were published December 2012 in the journal Case Reports in Dermatology by researchers from the Permanente Medical Group (Elk Grove, CA, USA) and SkinCare Physicians (Chestnut Hill, MA, USA).

Dr. Gertraud Kraehn-Senftleben, a dermatologists from Blaubeuren, Germany, and a member of the German Onkoderm Network, and one of the first clinicians to use the VivoSight OCT scanner in routine clinical practice, commented, “These studies reflect the day to day experience in our clinic. We routinely scan tumor margins prior to micrographic surgery and our experience of more than 150 patients is that it reduces the amount of repeat surgery required. This is a great benefit for both the patient and the dermatologist.”

Related Links:
Michelson Diagnostics
State University of New York Downstate Medical Center
SkinCare Physicians



SuperSonic Imagine
RADCAL
RTI ELECTRONICS AB

Channels

Radiography

view channel

Leading Cancer Center Among First in Europe to Treat Patients Using Robotic Patient-Positioning Radiotherapy Couch

A Viennese hospital has become one of the first oncology departments in Europe to introduce clinical treatments using a robotic radiotherapy patient-positioning couch. Kaiser-Franz-Josef Hospital (KFJ; Vienna, Austria) has introduced this enhanced patient positioning device, which enables more flexibility during radiotherapy... Read more

MRI

view channel

Use of Breast MRI Offers Optimized Care

Magnetic resonance imaging (MRI) is being used increasingly for breast cancer screening, diagnostic assessment, treatment planning, and monitoring; however, a recent study revealed that over time, the indication for breast MRI has changed. Much of the increase was found among women with breast cancer risk factors, but there... Read more

Ultrasound

view channel
Image: Analogic Sonic Window handheld ultrasound for peripheral IV placement (Photo courtesy of Analogic).

First-of-a-Kind Ultrasound System Designed for Image-Guided Peripheral Intravenous Access and Fits in Pocket

A new, ultra-compact ultrasound device provides direct visualization of structures beneath the skin in real time to effectively guide clinicians placing peripheral intravenous (IV) lines.... Read more

Nuclear medicine

view channel
Image: Micrograph of Hodgkin lymphoma. Lymph node fine-needle aspiration (FNA) specimen. Field stain (Photo courtesy of Wikimedia Commons).

Early PET-Negative Stage I/II Hodgkin Lymphoma Patients Show Increased Risk of Early Relapse when Radiotherapy Is Not Used

Analysis of a new study indicates an increased risk of early relapse when excluding radiotherapy in early positron emission tomography (PET) scan-negative patients with stage I/II Hodgkin’s lymphoma.... Read more

Imaging IT

view channel

Enterprise Image-Viewing System Receives FDA Clearance for Mobile Diagnosis on All Modalities

An enterprise image-viewing system is now cleared in the United States for diagnosis on mobile devices, for all imaging modalities (except mammography). Calgary Scientific, Inc. (Calgary, AB, USA) recently reported their latest Class II clearance from the US Food and Drug Administration (FDA). Calgary Scientific worked... Read more

Industry News

view channel

Collaboration Expands Capacity for Proton Therapy Clinical Research and Patient Treatments

Varian Medical Systems (Palo Alto, CA, USA) and the Paul Scherrer Institute (PSI; Villigen PSI, Switzerland) are extending an existing collaboration in the field of proton therapy to offer patients more accurate cancer treatments using intensity-modulated proton therapy (IMPT). Under the agreement, Varian will also... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.